The content on this site is intended for healthcare professionals only
Dr Ehninger presents on the results of a phase II randomised study on the safety and efficacy of sorafenib in leukaemia at a press conference at EHA 2015.
Read the news story for more.
Advancements in minimal residual disease detection in myeloma
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing 1st line TKI Wisely in patients with CML
Encouraging results using mismatched unrelated donors in stem cell transplantation
Multiple myeloma in a resource constrained setting
Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects
Relapsed refractory multiple myeloma
